Drugs / ABBV-303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06158958 | Feb 2024 → Oct 2025 | cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-05 | Dragonfly Therapeutics | Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303 dragonflytx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06158958 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT06158958 ↗ |